Jul 15, 2026 | Uncategorized
Hosp Pediatr. 2026 Jul 17:e2025009094. doi: 10.1542/hpeds.2025-009094. Online ahead of print.ABSTRACTBACKGROUND: Illicitly manufactured fentanyl (IMF) is the predominant opioid in the US drug supply and is a major contributor to morbidity and mortality during...
Jul 13, 2026 | Uncategorized
JAMA Netw Open. 2026 Jul 1;9(7):e2623280. doi: 10.1001/jamanetworkopen.2026.23280.ABSTRACTIMPORTANCE: Buprenorphine-naloxone and extended-release (XR) naltrexone are both efficacious medications for opioid use disorder that reduce unregulated opioid use and improve...
Jul 9, 2026 | Uncategorized
Subst Use Addctn J. 2026 Jul 10:29767342261463988. doi: 10.1177/29767342261463988. Online ahead of print.ABSTRACTBACKGROUND: Opioid treatment programs (OTPs), the only outpatient settings authorized to dispense methadone for opioid use disorder in the United States,...
Jul 6, 2026 | Uncategorized
BMJ Qual Saf. 2026 Jul 7:bmjqs-2025-019297. doi: 10.1136/bmjqs-2025-019297. Online ahead of print.ABSTRACTINTRODUCTION: Physician burnout is related to patient safety and quality of care. Female physicians face unique challenges which may contribute to higher...
Jul 3, 2026 | Uncategorized
Subst Abuse Treat Prev Policy. 2026 Jul 3. doi: 10.1186/s13011-026-00746-1. Online ahead of print.ABSTRACTBACKGROUND: The evolving U.S. drug market has fueled a public health crisis with rising drug use-associated morbidity and mortality, revealing a mismatch between...
Jun 30, 2026 | Uncategorized
Harm Reduct J. 2026 Jul 1. doi: 10.1186/s12954-026-01492-0. Online ahead of print.ABSTRACTINTRODUCTION: People who use drugs (PWUD) in the U.S. often face barriers to accessing harm reduction, social, and medical services, including fragmented systems and limited...
